Multiplicity considerations in subgroup analysis
Authors:
- 1 August 2017
- journal article
- review article
- Published by Wiley in Statistics in Medicine
- Vol. 36 (28) , 4446-4454
Abstract
This paper deals with the general topic of subgroup analysis in late‐stage clinical trials with emphasis on multiplicity considerations. The discussion begins with multiplicity issues arising in the context of exploratory subgroup analysis, including principled approaches to subgroup search that are applied as part of subgroup exploration exercises as well as in adaptive biomarker‐driven designs. Key considerations in confirmatory subgroup analysis based on one or more pre‐specified patient populations are reviewed, including a survey of multiplicity adjustment methods recommended in multi‐population phase III clinical trials. Guidelines for interpretation of significant findings in several patient populations are introduced to facilitate the decision‐making process and achieve consistent labeling across development programs. Copyright © 2017 John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Extension of adaptive alpha allocation methods for strong control of the family‐wise error rateStatistics in Medicine, 2012
- Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulationsStatistics in Medicine, 2011
- Chain Procedures: A Class of Flexible Closed Testing Procedures With Clinical Trial ApplicationsStatistics in Biopharmaceutical Research, 2011
- A consistency‐adjusted alpha‐adaptive strategy for sequential testingStatistics in Medicine, 2010
- Design and Analysis Considerations in Clinical Trials With a Sensitive SubpopulationStatistics in Biopharmaceutical Research, 2010
- Analysis of Multiple Endpoints in Clinical TrialsBayesian Methods in Health Economics, 2009
- Multiple Testing Methodology2009
- Some Controversial Multiple Testing Problems in Regulatory ApplicationsJournal of Biopharmaceutical Statistics, 2009
- Use of genomic signatures in therapeutics development in oncology and other diseasesThe Pharmacogenomics Journal, 2006
- Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive PatientsClinical Cancer Research, 2005